Jonathan Strosberg, MD
Medical Oncology · Tampa, FLNPI 1013960988
Payments from drug & device makers
Across 407 payments — averaging $23,816 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$8.1M
- E.r. Squibb & Sons, L.L.C.$785K
- Novartis$397K
- Exelixis Inc.$102K
- Advanced Accelerator Applications$87K
- Boehringer Ingelheim$67K
- plus $129K from 19 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 193 | $8,126,099 |
| E.r. Squibb & Sons, L.L.C. | 2 | $784,864 |
| Novartis | 19 | $397,487 |
| Exelixis Inc. | 43 | $101,575 |
| Advanced Accelerator Applications | 12 | $87,138 |
| Boehringer Ingelheim | 15 | $67,131 |
| Ipsen Biopharmaceuticals, Inc | 47 | $54,614 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $15,326 |
| Tersera Therapeutics LLC | 10 | $12,661 |
| Sun Pharmaceutical Industries Inc. | 4 | $8,800 |
| Boehringer Ingelheim International GmbH | 4 | $8,100 |
| Terumo Medical Corporation | 7 | $7,875 |
| Curium US LLC | 12 | $5,116 |
| Sanofi | 3 | $4,206 |
| Lexicon Pharmaceuticals, Inc. | 5 | $3,222 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 19 | $2,376 |
| Chiasma, Inc. | 2 | $1,800 |
| Delcath Systems | 2 | $1,661 |
| Bard Peripheral Vascular, Inc. | 1 | $1,300 |
| Organon | 1 | $998 |
| AstraZeneca | 1 | $238 |
| Progenics Pharmaceuticals, Inc. | 1 | $134 |
| Amgen | 1 | $109 |
| Amryt Pharma Holdings Ltd | 1 | $81 |
| Bayer | 1 | $29 |
How this compares
$9,692,939 in reported general payments places this provider in the 95th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Tampa
- Zeynep ErogluTampa$30.9M
- Jad ChahoudTampa$21.8M
- Patrick HwuTampa$18M
- Adil DaudTampa$13.3M
- Jingsong ZhangTampa$7.9M
- Sameh GaballaTampa$7.8M
- Alberto ChiapporiTampa$7.4M
- Christine ChungTampa$6.6M
- Mihaela DrutaTampa$5.6M
- Hyo HanTampa$5.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.